Biopharmx Corp (NYSE:BPMX) saw a significant growth in short interest in the month of April. As of April 13th, there was short interest totalling 3,440,526 shares, a growth of 33.3% from the March 31st total of 2,580,087 shares. Approximately 7.3% of the company’s stock are short sold. Based on an average daily volume of 2,286,701 shares, the short-interest ratio is currently 1.5 days.
Separately, Roth Capital set a $3.00 price objective on shares of Biopharmx Corp and gave the company a “buy” rating in a research note on Thursday, February 9th.
Shares of Biopharmx Corp (NYSE:BPMX) traded up 8.9111% during mid-day trading on Friday, hitting $0.4901. 1,462,431 shares of the company were exchanged. The stock’s market cap is $33.19 million. Biopharmx Corp has a 12-month low of $0.19 and a 12-month high of $1.22. The stock’s 50-day moving average price is $0.63 and its 200 day moving average price is $0.46.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.